333 W. SANTA CLARA STREET, SUITE 900, SAN JOSE, CA
Financial Results, Other Events
Shareholder votes
Reports Initial Revenues from RenovoCath® Commercialization, and Provides Update on Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial
Announces Pricing of $12.1 Million Underwritten Public Offering of Common Stock
Earnings Release
Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians
Changing the Company's Accountant
Q1
Notice of Late Filing for Annual Report
Q3
Q2
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
S-8 POS